Phase I
Prokarium, a private biotechnology company developing vaccines against infectious diseases and immunotherapy for solid tumors, has received Clinical Trial Authorization acceptance from the UK Medicines and Healthcare products Regulatory Agency to run a first-in-human Phase I trial with Entervax™, a bivalent vaccine against enteric fever.
Jonathan Cotliar, chief medical officer of Science 37, a leader in virtual clinical trials, took time to speak with BioSpace about virtual and hybrid clinical trials, the CNS Summit and Science 37.
In its announcement, Solid Biosciences said a patient in its second cohort who was dosed in October experienced a serious adverse event that was deemed related to the drug.
The drug failed to meet the primary endpoints of progression-free survival and overall response rate.
A clinical Phase II safety and efficacy trial is planned for 2020 for the treatment of influenza, an indication with a very high unmet medical need
It was a busy week for clinical trial updates for the first week of November. Here’s a look.
Martinsried/ Munich Medigene AG announces that immune monitoring data during the first year of treatment from the ongoing Phase I / II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia will be presented at the upcoming ASH Annual Meeting taking place 7 - 10 December 2019 in Orlando, Florida, USA.
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer.
BioSpace has put together a list of the top 10 indications that have been or are the subject of being researched across the region by pharma companies, academic institutions and other organizations. The trials range from Phase I to Phase III.
San Diego-based Mirati Therapeutics announced the first clinical data from its Phase I/II clinical trial of MRTX849 in solid tumors. MRTX849 is a KRAS G12C inhibitor.
PRESS RELEASES